HUTCHISON PATRICK 4
4 · BIOSPECIFICS TECHNOLOGIES CORP · Filed Dec 2, 2020
Insider Transaction Report
Form 4
Hutchison Patrick
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-12-02$32.29/sh−10,000$322,900→ 0 totalExercise: $56.21Exp: 2030-01-06→ Common Stock (10,000 underlying)
Footnotes (1)
- [F1]Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (January 6, 2020), were canceled in exchange for a cash payment of $322,900.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.